PHARMACIES ENGELS
ActivePHARMACIES ENGELS has been active since 2009 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €1.06M and a net result of €187k. Equity is growing by ~18% per year across the filed fiscal years. Its solvency ranks better than 75% of 10242 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.8% (low).
Checked score
Score 2025
93
/ 100
Excellent▼ -7 vs 2024
The score combines four axes. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability89▼-11
Solvency99=
Growth78=
Stability100
Bankruptcy probability, 12 months
0.8%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €100k at 30 days acceptable
Liquidity ample (current ratio 2.94 against 3.14 in 2024), and 37.6% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Eight signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
62.4%
Return on assets
11.1%
Age of the figures
9 mo
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 10-07-2026, 21 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
21 d early
2024
64 d early
2023
68 d early
2022
3 d late
2021
16 d early
2020
32 d early
2019
16 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
16-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€187k▼ 21.1%
2024 · €238k
2018: €76k
2019: €77k
2020: €77k
2021: €144k
2022: €133k
2023: €191k
2024: €238k
2018 → 2025
Working capital
€704k▼ 15.7%
2024 · €836k
2018: €137k
2019: €239k
2020: €301k
2021: €385k
2022: €481k
2023: €704k
2024: €836k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€519k-€600k▲ 15.6%€765k▲ 27.4%€926k▲ 21.2%€1.06M▲ 14.0%
Operating result€209k-€197k▼ 5.8%€278k▲ 41.5%€340k▲ 22.4%€272k▼ 20.2%
Net result€144k-€133k▼ 7.5%€191k▲ 43.9%€238k▲ 24.3%€187k▼ 21.1%
Result per fiscal year
Operating resultNet result
The operating result falls in 2025; 2025 is 20% below 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €1.69M
Fixed assets
€624k▲ 186%
Current assets
€1.07M▼ 12.9%
Equity and liabilities €1.69M
Equity
€1.06M▲ 14.0%
Provisions
€3k▼ 33.3%
Debt
€633k▲ 23.1%
The debt ratio rises from 35.6% to 37.4%: debt grows faster than equity.
Key figures and ratios
EBITDA
€332k▼
2024 · €364k
Cash flow
€248k▼
2024 · €261k
Solvency
62.4%▼
2024 · 64.1%
Current ratio
2.94▼
2024 · 3.14
Quick ratio
2.00▼
2024 · 2.43
Debt / equity
0.60▲
2024 · 0.55
ROE
17.7%▼
2024 · 25.6%
ROA
11.1%▼
2024 · 16.4%
Interest coverage
18.82▼
2024 · 64.37
Debt
€633k▲
2024 · €514k
Debt ≤ 1 year
€364k▼
2024 · €391k
Debt > 1 year
€263k▲
2024 · €121k
Income taxes
€72k▼
2024 · €106k
Staff costs
€400k▲
2024 · €375k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€1.44M€1.69M▲
Fixed assets21/28€218k€624k▲
Tangible fixed assets22/27€218k€624k▲
Plant, machinery and equipment23€42k€566k▲
Furniture and vehicles24€72k€58k▼
Assets under construction and advance payments27€104k-
Current assets29/58€1.23M€1.07M▼
Stocks and contracts in progress3€277k€342k▲
Stocks30/36€277k€342k▲
Amounts receivable within one year40/41€237k€209k▼
Trade receivables40€204k€190k▼
Other amounts receivable41€32k€18k▼
Current investments50/53€65k€195k▲
Cash at bank and in hand54/58€640k€306k▼
Deferred charges and accrued income490/1€8k€17k▲
Equity and liabilities
Total equity and liabilities10/49€1.44M€1.69M▲
Equity10/15€926k€1.06M▲
Contributions10/11€19k€19k=
Reserves13€907k€1.04M▲
Tax-exempt reserves132€13k€8k▼
Distributable reserves133€895k€1.03M▲
Profit (loss) carried forward14€251€998▲
Provisions and deferred taxes16€4k€3k▼
Deferred taxes168€4k€3k▼
Amounts payable17/49€514k€633k▲
Amounts payable after more than one year17€121k€263k▲
Financial debts170/4€121k€263k▲
Amounts payable within one year42/48€391k€364k▼
Current portion of amounts payable after more than one year42€35k€36k▲
Trade debts44€194k€102k▼
Suppliers440/4€194k€102k▼
Taxes, remuneration and social security45€116k€99k▼
Taxes450/3€55k€39k▼
Remuneration and social security454/9€62k€60k▼
Other amounts payable47/48€45k€127k▲
Accrued charges and deferred income492/3€2k€6k▲
Income statement
Code20242025
Remuneration, social security and pensions62€375k€400k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€24k€60k▲
Other operating charges640/8€1k€945▼
Gross operating margin9900€740k€733k▼
Operating profit (loss)9901€340k€272k▼
Financial income75/76B€8k€4k▼
Recurring financial income75€8k€4k▼
Financial charges65/66B€6k€18k▲
Recurring financial charges65€6k€18k▲
Profit (loss) for the period before taxes9903€342k€258k▼
Transfer from deferred taxes780€1k€1k=
Income taxes67/77€106k€72k▼
Profit (loss) for the period9904€238k€187k▼
Transfer from tax-exempt reserves789€4k€4k=
Profit (loss) for the period to be appropriated9905€242k€192k▼
Appropriation of the result
Profit (loss) to be appropriated9906€242k€192k▼
Profit (loss) brought forward from the previous period14P€297€251▼
Transfer from equity791/2€75k€57k▼
Transfer to equity691/2€241k€190k▼
To other reserves6921€241k€190k▼
Profit to be distributed694/7€76k€58k▼
Return on contributions (dividend)694€76k€58k▼
Social balance
Average headcount (FTE)90876.06.1▲
The notes to these accounts (10 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
10-07
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
31-12
Financial
Equity above €1MEq €1.06M ▲14%
8 profitable years in a row build equity to €1.06M.
28-05
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
31-12
Financial
Highest result since 2018net €238k ▲24.3%
Operating result €340k, net result €238k, both a record.
24-05
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
2023
03-08
NBB filing
Annual accounts filed
fiscal year 2022 · full schema · 3 days late
2022
15-07
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
2021
31-12
Financial
Equity above €500kEq €519k ▲15.8%
4 profitable years in a row build equity to €519k.
29-06
NBB filing
Annual accounts filed
fiscal year 2020 · full schema
2020
15-07
NBB filing
Annual accounts filed
fiscal year 2019 · full schema
2019
11-07
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
2018
30-07
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
2017
06-07
NBB filing
Annual accounts filed
fiscal year 2016 · full schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
3 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Malmedy · 2 establishment units since 2009
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Rue Neuve 484960 MalmedyGround area
417 m²
Building footprint
127 m²
Volume, LiDAR
964 m³
2 parcels, Wallonia · tallest building 12.9 m, ±3 floors. Linked by address, not a title deed.
2 establishment units
PHARMACIES ENGELS
since 20092.183.743.578
PHARMACIES ENGELS
since 20092.183.744.073
2 parcels
Wallonia
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 63049C0701/00A000 | Wallonia | 276 m² | 1 · 40 m² | 10.3 m · 1 fl. |
| 63049C0364/00K000 | Wallonia | 142 m² | 1 · 87 m² | 12.9 m · 3 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Recognitions · licences · registrations
Food safety, FASFC
2 sitesMalmedy2.183.743.578
Malmedy2.183.744.073
Similar companies · same sector, comparable size
PHARMACOZ
BE 0425.551.173
Gerpinnes · Eq €1.05M
PharmaléaH
BE 0777.699.280
Watermaal-Bosvoorde · Eq €1.06M
PHARMACIE MATHIEU
BE 0882.228.955
Sivry-Rance · Eq €1.05M
VINVEST
BE 0451.022.086
Edegem · Eq €1.05M
PHARMACIE DU BATY
BE 0464.919.515
Profondeville · Eq €1.06M
Of 5,209 companies in sector 47730 we hold annual accounts for 3,851. 2,967 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded16-12-2009
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
47750Retail sale of cosmetics and toilet articles
Sources
Crossroads Bank for EnterprisesNational Bank · 16 filingsAddress and cadastre registers
Data from official sources, last processed on 15-09-2026. Scores and ratios are computed by Checked and are not a credit decision.